Zaini Rana G, Al-Rehaili Amani A
Deanship of Community Service and Sustainable Development, Taif University, Taif, Saudi Arabia.
College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
J Oncol. 2019 Jan 1;2019:5981054. doi: 10.1155/2019/5981054. eCollection 2019.
Regulatory T cells (Treg cells) are considered one of the main dynamic cell types within the immune system. Because Treg cells suppress immune responses, they have potential roles in immunological self-tolerance and may help to maintain immune homeostasis. Promoting Treg cell function and increasing their numbers might be useful in treating autoimmune disorders, as well as preventing allograft rejection. However, studies of mice and humans demonstrate that Treg cells promote cancer progression and suppress antitumor immunity. Therefore, suppressing Treg cell function or reducing their numbers could support the immune system's response to pathogenic microorganisms and tumors. As a result, there is great interest in investigating the Treg cells role in the treatment of hematological and nonhematological malignancies. Consequently, Treg cells could be a fundamentally important target for pathologies of the immune system. Targeting effector Treg cells could help to distinguish and selectively decrease these cells while preserving other Treg cells needed to suppress autoimmunity. Currently, a promising way to treat malignancies and other autoimmune disorders is stem cell transplantation. Stem cell transplants (SCT) can help to manage the production of Treg cells and also may produce more efficient Treg cells, thereby suppressing clinical disease progression. Specifically, mature T cells within the engrafted stem cells mediate this SCT beneficial effect. During SCT, the recipient's immune system is replaced with a donor, which allows for improved immune system function. In addition, SCT can protect from disease relapse, as graft-versus-host disease (GvHD) in transplant patients can be protective against cancer recurrence. The current review will define the role of regulatory T cells in treatment of malignancy. Additionally, it will summarize current promising research regarding the utility of regulatory T cells in stem cell transplantation.
调节性T细胞(Treg细胞)被认为是免疫系统中主要的动态细胞类型之一。由于Treg细胞会抑制免疫反应,它们在免疫自身耐受中具有潜在作用,并可能有助于维持免疫稳态。促进Treg细胞功能并增加其数量可能对治疗自身免疫性疾病以及预防同种异体移植排斥有用。然而,对小鼠和人类的研究表明,Treg细胞会促进癌症进展并抑制抗肿瘤免疫。因此,抑制Treg细胞功能或减少其数量可能有助于免疫系统对病原微生物和肿瘤作出反应。结果,人们对研究Treg细胞在血液系统和非血液系统恶性肿瘤治疗中的作用非常感兴趣。因此,Treg细胞可能是免疫系统疾病的一个根本重要靶点。靶向效应性Treg细胞有助于区分并选择性减少这些细胞,同时保留抑制自身免疫所需的其他Treg细胞。目前,治疗恶性肿瘤和其他自身免疫性疾病的一种有前景的方法是干细胞移植。干细胞移植(SCT)有助于控制Treg细胞的产生,还可能产生更有效的Treg细胞,从而抑制临床疾病进展。具体而言,植入的干细胞内的成熟T细胞介导了这种SCT的有益作用。在SCT过程中,受体的免疫系统被供体的免疫系统所取代,这使得免疫系统功能得到改善。此外,SCT可以预防疾病复发,因为移植患者的移植物抗宿主病(GvHD)可以预防癌症复发。本综述将定义调节性T细胞在恶性肿瘤治疗中的作用。此外,它将总结目前关于调节性T细胞在干细胞移植中的效用的有前景的研究。